Ruben Colman, MD, PhD

Peds GI/IBD Physician Scientist & Director of Intestinal Ultrasound @StanfordPedsGI | #PrecisionMed #ClinPharm #Microbiome | Improving Outcomes ➡️ Innovation

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

🚨 Exciting news in Crohn’s disease care!

FDA approves subcutaneous SKYRIZI induction, offering patients greater flexibility and convenience.

A welcome step toward making effective IBD treatment fit patients’ lives!

#IBD #CrohnsDisease #IBDLibrary

https://t.co/MYYZbG1spG

[iUSCAN @iUSCAN]

New for families: our iUSCAN Pediatrics Committee’s illustrated guide helps children, parents & caregivers know what to expect at an intestinal ultrasound visit.

Read, download & print for your clinic:
https://t.co/PdoDFjgNDU

#IntestinalUltrasound #IBD

[Charlie Lees @charlie_lees]

Risankizumab was the first p19 IL-23 blocker licensed for Crohn's, nearly three years ahead of guselkumab. But guselkumab arrived with subcutaneous induction from day one.

That matters. Infusion suites are full, and in the US an iv start followed by subcut maintenance can mean two separate insurance approvals, where an all-subcut route needs one.

AFFIRM is the sc induction data for risa. First shown by press release in March, the first congress presentation was last night - Millie Long at ACG in Nashville (along with updated press release). Silvio Danese presents the data at UEG on Monday at 16:00.

The regimen is 720 mg subcutaneously at weeks 0, 2, 4 and 8, then 360 mg every eight weeks from week 12. Guselkumab's subcutaneous induction is 400 mg at weeks 0, 4 and 8 (then 100mg q8w or 200mg q4w maintenance).

In 289 people with Crohn's disease, two-thirds of whom had already failed an advanced therapy, week 12 clinical remission was 55% v 30% and endoscopic response 44% v 14%, roughly where intravenous induction landed in ADVANCE. Endoscopic remission was 28% v 10%. The benefit was largest in patients new to advanced therapy, with endoscopic response of 61% v 15%, against 35% v 14% after advanced therapy failure.

AbbVie expects FDA approval later this year, and the EMA has been reviewing it since August, so Europe will probably follow in 2027.

[NEJM @NEJM]

In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo. Full ANTHEM-UC trial results: https://t.co/PIsfoXCmTK

[Michael J Rosen, MD, MSCI @DrRosenIBD]

👏 to @SMCH_IBD_Celiac faculty @patelperseus @JonathanMoses77, & lead auth @JeremyAdlerMD on their @AGA_CGH pub: inappropriate 5-ASA use in peds #CrohnsDisease is associated with ⬆️ steroid use and ⬇️ biologic durability. @sabpeds @DrPasternak_IBD https://t.co/dTVdd8mK8N

[Amelia Kellar @amelia_kellar]

Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn’s disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN https://t.co/8ZnWBlX7qu

[Amelia Kellar @amelia_kellar]

FDA expands Stelara use to children with ulcerative colitis https://t.co/Ac4bhLVInn

[Sabina Ali,MD @sabpeds]

Aminosalicylate use Increases Corticosteroid Exposure and Decreases Bi... https://t.co/m8rlInHMfe by the “BISCUIT Study team” @JeremyAdlerMD @patelperseus @DrPasternak_IBD @JonathanMoses77 DavidSuskind CharlesSamson JessKaplan

[Ruben Colman, MD, PhD @ColmanMD]

@IBDJournals Congrats @AlsoudDahham and all!

[Shrinivas Bishu @IBDimmunology]

ASUC and IFX - 5 or 10 mg/kg? Consider post-hoc of PREDICT-UC @AmerGastroAssn @AGA_Gastro

▶️data for 10 mg/kg = low
▶️maybe 🔑 is selective adaptive dosing?

⬆️ IFX clearance = responds to ⬆️ Dose IFX.

maybe 🔑 = target those who should intensify?

https://t.co/Hehg0sTCPs

[Michael J Rosen, MD, MSCI @DrRosenIBD]

🚨 Now accepting applications: Advanced Pediatric IBD Fellowship @SMCH_IBD_Celiac! One year, 50% protected research time, POCUS training with world experts, mentorship from 7 IBD faculty leaders, kind and driven team. July 2027–2028. Apply: https://t.co/7m1lxyoJiW

[David Choi, PharmD @IBDPharmD]

Update: Tofacitinib generics have officially launched and being dispensed. There are true generics and you can confirm with the FDA Orange Book regarding therapeutic equivalence/automatic substitutions. #IBD #GItwitter

https://t.co/8i77iFBjAN

[Michael J Rosen, MD, MSCI @DrRosenIBD]

Beyond excited to welcome Dr. Michael Schumacher, PhD (@schumacherama) to @SMCH_IBD_Celiac and @StanfordPedsGI as Asst. Professor & Endowed Faculty Scholar! 🧵

[Ruben Colman, MD, PhD @ColmanMD]

Truly honored to receive the 2026 @Stanfordchild early career clinical excellence award! Grateful to work with the best colleagues at @StanfordPedsGI and @SMCH_IBD_Celiac

[Stanford Pediatric Gastroenterology @StanfordPedsGI]

Congratulations to Dr. Ruben Colman, recipient of the Department of Pediatrics’ Early Career Clinical Excellence Award! 🎉 Celebrating his commitment to exceptional patient care and advancing pediatric medicine.

[Ruben Colman, MD, PhD @ColmanMD]

Fortunate to work with the excellent @SMCH_IBD_Celiac team every day! @StanfordChild - @DrRosenIBD @JonathanMoses77 @hilaryjericho @askIBDdoc @patelperseus @Peds_Pharm_D @fmardini_rd

[Stanford Children's @StanfordChild]

At our Stanford Medicine Children's Health Center for IBD and Celiac Disease, children of all ages receive expert, holistic care designed to support their full well-being — from digestive health to mental health and great nutrition. https://t.co/HIE05ojg4c

[Ruben Colman, MD, PhD @ColmanMD]

Exciting #postdoc opportunity in the Precision Therapeutics for IBD - Colman Lab! @Stanford - Focus on innovative #Pharmacometrics applications and #microbiome biomarkers - https://t.co/KtgS2YB2ge

[Ruben Colman, MD, PhD @ColmanMD]

Exciting #postdoc opportunity in the Precision Therapeutics for IBD - Colman Lab! @Stanford - Focus on innovative #Pharmacometrics applications and #microbiome biomarkers - https://t.co/KtgS2YB2ge

[IBDJournal & CC360 @IBDJournals]

New Review👀

❗️1/2 of children w/ #IBD experience @ least one immune-mediated EIM

🩻Musculoskeleton manifestations were the most commonly reported

🔗Read more here: https://t.co/KQCQ1IkW2f

[NEJM @NEJM]

Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: https://t.co/C5oIChPFbG

Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation https://t.co/Ja8nORGjYr

[NASPGHAN @NASPGHAN]

NASPGHAN Foundation grant opportunities are available to support pediatric GI research, training, nutrition, QI, advocacy, nursing, dietitian research, and more. Explore current opportunities+share with eligible colleagues. https://t.co/xzIqaHW59N
#NASPGHAN #PediatricGI